Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Tuebingen – page 42

607 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
607
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

607 trials in Tuebingen

Open in trial search

Study on the Effects of Dexamethasone in Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Psoriasis

Not recruiting

Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Effects of Riliprubart for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on cutaneous lupus erythematosus and psoriatic arthritis, evaluating novel therapeutic approaches for managing chronic inflammatory conditions.

  • Lupus skin manifestations
  • Joint inflammation
  • Autoimmune responses

Studies aim to assess new treatment options for improving patient outcomes and quality of life.

02 Oncology Research

Comprehensive studies on various cancer types, including metastatic prostate cancer and basal cell carcinoma, exploring innovative treatment combinations.

  • Advanced cancer therapies
  • Pediatric liver tumors
  • Targeted treatments

Research focuses on improving survival rates and developing more effective treatment strategies.

03 Neurological Disorders

Groundbreaking research in multiple system atrophy and seizure disorders, investigating new therapeutic approaches for complex neurological conditions.

  • Brain function disorders
  • Movement disorders
  • Epilepsy management

Clinical trials aim to enhance treatment options for patients with challenging neurological conditions.

04 Ophthalmology Studies

Advanced research in eye disorders, including Leber congenital amaurosis and geographic atrophy, focusing on innovative treatment approaches.

  • Retinal diseases
  • Visual function
  • Gene therapy

Trials aim to preserve and improve vision in patients with rare and progressive eye conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.